Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Velsera Technology Achieves Milestone with FDA Approval of Illumina TruSight™ Oncology Comprehensive IVD, Advancing Cancer Diagnostics

NextEdge Admin

16 Sep 2024

2 min 22 sec

Illumina,precision medicine,targeted therapies

Velsera, a global leader in healthcare technology, is proud to announce that its advanced tumor profiling technology is a key component of the Illumina TruSight™ Oncology (TSO) Comprehensive IVD results report. By integrating Velsera’s cutting-edge knowledge base (KB), the TSO Comprehensive test enhances patient care through personalized treatment, providing nationwide access to precision oncology.

The collaboration between Velsera and Illumina, which began in December 2018, was driven by a mutual commitment to advancing cancer diagnostics and expanding access to targeted therapies. Velsera’s KB plays a critical role in helping laboratories adopt NGS-based diagnostics with increased accuracy and efficiency.

“Our partnership with Velsera has been instrumental in developing the TruSight™ Oncology Comprehensive test, enabling labs to simplify the identification of key cancer biomarkers,” said Nicki Berry, Head of Region-Americas at Illumina.

Velsera’s KB aids in the classification of cancer mutations, distinguishing between those with clinical or potential clinical significance. This supports more personalized treatment plans, improving patient outcomes.

“Making targeted therapeutics more accessible globally remains our priority,” said Jamie Littlejohns, CEO of Velsera. “This milestone demonstrates our dedication to translating research into real-world clinical applications that benefit cancer patients across the U.S.”

As a leader in precision medicine, Velsera continues to collaborate with industry giants like Illumina to drive innovations in cancer diagnostics. Their joint efforts accelerate the development of in vitro diagnostic (IVD) solutions, setting a new standard for biomarker identification and advancing patient care globally.